Evan T Keller
Richard and Susan Rogel Professor of Oncology
Professor of Urology
Professor of Pathology
Associate Professor of Comparative Pathology
Department of Laboratory Animal Medicine
Program Associate, Urology
Shared Services and Center Director, UMOR Office of VP for Research
[email protected]

Available to mentor

Evan T Keller
Professor
  • About
  • Links
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
  • About

    Evan T. Keller, DVM, PhD is a Professor of Urology and Pathology, School of Medicine, University of Michigan. He is Director of the Single Cell Spatial Analysis Program; Associate Director for Shared Resource for the University of Michigan Comprehensive Rogel Cancer Center; Directs an NIH-funded Program Project on Prostate Cancer Bone Metastasis; and Co-Director of the Single Cell Analysis Core. Dr. Keller obtained Doctor of Veterinary Medicine (DVM) and Master of Preventive Veterinary Medicine (MPVM) degrees at University of California and attained American College of Veterinary Internal Medicine certification in Oncology and a PhD in Developmental Biology at the University of Wisconsin, Madison. His areas of research include (1) prostate cancer metastasis research, with a special emphasis on bone metastasis and the tumor microenvironment and (2) single cell and spatial analytic methods. Key research accomplishments include (1) defining importance of osteoclastic activity and targeting it in prostate cancer leading to clinical use of RANKL inhibitor (Denosumab); (2) identification of raf kinase inhibitor protein (RKIP) as a novel metastasis suppressor gene; (3) determining the importance of the Wnt pathway in bone metastasis; and (4) defining interleukin-6 as a contributor to castration resistant prostate cancer.

    Links
    • https://sites.google.com/umich.edu/keller-lab/home
    Qualifications
    • DVM
      University of California, Davis, United States
    • MPVM
      University of California, Davis, Ann Arbor
    • PhD
      University of Wisconsin, Madison, United States
    Center Memberships
    • Center Member
      Center for Computational Medicine and Bioinformatics
    • Center Member
      Rogel Cancer Center
    • Center Member
      Global REACH
    • Center Member
      Biointerfaces Institute
    • Center Member
      Caswell Diabetes Institute
    • Center Member
      Precision Health Initiative
    Research Overview

    Research interests include (1) prostate cancer metastasis research, with a special emphasis on bone metastasis and the tumor microenvironment; (2) single cell analytic methods; (3) drug resistance; (4) spatial analytics.

    Recent Publications See All Publications
    • Preprint
      Complement C3d enables protective immunity capable of distinguishing spontaneously transformed from non-transformed cells.
      Platt JL, Zhao C, Chicca J, Pianko MJ, Han J, The S, Rao A, Keller E, de Mattos Barbosa MG, Naing L, Pasieka-Axenov T, Axenov L, Schaefer S, Farkash E, Cascalho M. 2024 Jul 31; DOI:10.1101/2024.07.31.606044
      PMID: 39211250
    • Journal Article
      Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer.
      Dong L, Hu C, Ma Z, Huang Y, Shelley G, Kuczler MD, Kim C-J, Witwer KW, Keller ET, Amend SR, Xue W, Pienta KJ. Med Oncol, 2024 Jun 5; 41 (7): 169 DOI:10.1007/s12032-024-02400-x
      PMID: 38839666
    • Journal Article
      PD16-04 SPATIAL ANALYSIS OF PRIMARY AND METASTATIC LESIONS IN SARCOMATOID RENAL CELL CARCINOMA REVEALS INSIGHT TO TUMOR BIOLOGY AND IMMUNE MICROENVIRONMENT
      May AM, Williams C, Hagler S, McNiff M, Robinson T, Salami S, Udager A, Keller ET. Journal of Urology, 2024 May; 211 (5S): e366 DOI:10.1097/01.ju.0001009560.23593.56.04
    • Journal Article
      PD16-05 EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) AND PD-1/PD-L1 SIGNALING PROVIDE RECIPROCAL FEEDBACK IN RENAL CELL CARCINOMA PROGRESSION WITH IMPLICATIONS FOR IMMUNOTHERAPY RESPONSE
      May AM, Wainstein M, McGue J, Robinson T, Mehra R, Salami SS, Frankel T, Udager A, Keller ET. Journal of Urology, 2024 May; 211 (5S): e367 DOI:10.1097/01.ju.0001009560.23593.56.05
    • Preprint
      Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer.
      Dong L, Hu C, Ma Z, Huang Y, Shelley G, Kuczler MD, Kim C-J, Witwer KW, Keller ET, Amend SR, Xue W, Pienta KJ. 2024 Mar 29; DOI:10.21203/rs.3.rs-4164213/v1
      PMID: 38585988
    • Proceeding / Abstract / Poster
      EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) AND PD-1/PD-L1 SIGNALING PROVIDE RECIPROCAL FEEDBACK IN RENAL CELL CARCINOMA PROGRESSION WITH IMPLICATIONS FOR IMMUNOTHERAPY RESPONSE
      Wainstein MD, McGue J, Robinson T, Mehra R, Salami SS, Frankel T, Udager A, Keller ET, May AM, Jiang J. Urologic Oncology Seminars and Original Investigations, 2024 Mar; 42: s5 - s6. DOI:10.1016/j.urolonc.2024.01.048
    • Proceeding / Abstract / Poster
      Association of transitional gradient from clear cell to sarcomatoid renal cell carcinoma with macrophage/tumor cell crosstalk.
      May A, Williams C, The S, McGue J, Wainstein M, Shelley G, Robinson T, Salami SS, Mehra R, Frankel T, Udager AM, Keller ET. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): 480 - 480. DOI:10.1200/jco.2024.42.4_suppl.480
    • Journal Article
      Differences in mutations across tumour sizes in clear-cell renal cell carcinoma.
      Monda SM, Carney BW, May AM, Gulati S, Salami SS, Chandrasekar T, Keller ET, Huebner NA, Palapattu GS, Dall'Era MA. BJU Int, 2024 Sep 12; DOI:10.1111/bju.16527
      PMID: 39263870